Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445322 · ClinicalTrials.gov registry record
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
A clinical trial of Stargardt Disease and Cone-Rod Dystrophy, sponsored by Ascidian Therapeutics.
- Recruiting
- Registry status
- 50
- Enrollment target
- 8
- Study locations
NCT06445322 is a study of Stargardt Disease and Cone-Rod Dystrophy that is actively recruiting participants, run by Ascidian Therapeutics. The registered enrollment target is 50 participants, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06445322, a study of Stargardt Disease and Cone-Rod Dystrophy, is actively recruiting participants, sponsored by Ascidian Therapeutics.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prescreening Assessments
Study Locations (8)
Texas
- Retina Foundation of Texas - Dallas
- Retina Consultants of Texas - Houston
California
- University of San Francisco - San Francisco
Florida
- Vitreo Retinal Associates - Gainesville
Maryland
- Wilmer Eye Institute at John Hopkins - Baltimore
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
Ohio
- Cincinnati Eye Institute - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2030-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445322
The ClinicalTrials.gov registry entry for NCT06445322 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (43% lower). The listed sponsor is Ascidian Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Prescreening Assessments is the first listed.
NCT06445322 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06445322 about?
NCT06445322 is a clinical study titled "Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)". This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
What is the current status of trial NCT06445322?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-06-20. Estimated completion is 2030-08-31.
What conditions does trial NCT06445322 study?
This clinical trial studies the following conditions: Stargardt Disease, Cone-Rod Dystrophy, Stargardt Disease 1, Juvenile Macular Degeneration.
What interventions are being tested in trial NCT06445322?
The interventions under investigation include: Prescreening Assessments (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06445322?
This trial is sponsored by Ascidian Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445322 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.